Non small cell lung cancer medical therapy metastatic cancer: Difference between revisions
No edit summary |
|||
Line 17: | Line 17: | ||
* Not specified non-small cell lung cancer</div>|B02=[[Squamous cell carcinoma of the lung|Squamous cell carcinoma]]}} | * Not specified non-small cell lung cancer</div>|B02=[[Squamous cell carcinoma of the lung|Squamous cell carcinoma]]}} | ||
{{familytree | | | | | |!| | | | | | | | | |!| | | }} | {{familytree | | | | | |!| | | | | | | | | |!| | | }} | ||
{{familytree | | | | | | {{familytree | | | | | |!| | | | | | | | | C02 | | | C02=Is the patient a smoker or former smoker?}} | ||
{{familytree | |,|-|-|-| | {{familytree | | | | | |!| | | | | | | |,|-|^|-|.| | | | |}} | ||
{{familytree | D01 | | D02 | | D03 | | | | {{familytree | | | | | |!| | | | | | | Y01 | | Y02 | | | | | Y01=Yes|Y02=No}} | ||
{{familytree | |!| | | |!| | | |!| | | | |}} | {{familytree | | | | | |!| | | | | | | |!| | | |!| | | }} | ||
{{familytree | E01 | | E02 | | E03 | | | E01=[[Non small cell carcinoma of the lung medical therapy#Positive sensitizing EGFR mutation|Click here for the sensitizing EGFR mutation specific treatment]]|E02=[[Non small cell carcinoma of the lung medical therapy#Positive ALK mutation|Click here for the specific therapy for the ALK mutation specific treatment]]|E03=[[Non small cell carcinoma of the lung medical therapy#Negative EGRF and ALK or unknown mutation|Click here for the treatment of negative sensitizing EGFR and ALK mutation metastatic disease]]}} | {{familytree | | | | | Z01 | | | | | | Z02 | | |!| | | | | Z01=Perform specific [[EGFR]] and ALK [[mutation]] testing: What is the specific [[mutation]]?|Z02=Perform specific [[EGFR]] and ALK [[mutation]] testing: Is there a mutation in any of those genes present?}} | ||
{{familytree | | | | | |!| | | | | |,|-|^|-|.| |!| | | |}} | |||
{{familytree | | | | | |!| | | | | W01 | | W02 |!| | | | W01=Yes|W02=No}} | |||
{{familytree | | | | | |`|-|-|v|-|-|'| | | |`|v|'| | | |}} | |||
{{familytree | | | | |,|-|-|-|+|-|-|-|.| | | |!|}} | |||
{{familytree | | | | D01 | | D02 | | D03 | | D04 | | | | D01=Sensitizing [[EGFR]] mutation|D02=ALK mutation|D03=Negative [[EGFR]] and ALK|D04=[[Non small cell carcinoma of the lung medical therapy#Metastatic squamous cell carcinoma|Click here for the squamous cell carcinoma specific treatment]]}} | |||
{{familytree | | | | |!| | | |!| | | |!| | | | |}} | |||
{{familytree | | | | E01 | | E02 | | E03 | | | E01=[[Non small cell carcinoma of the lung medical therapy#Positive sensitizing EGFR mutation|Click here for the sensitizing EGFR mutation specific treatment]]|E02=[[Non small cell carcinoma of the lung medical therapy#Positive ALK mutation|Click here for the specific therapy for the ALK mutation specific treatment]]|E03=[[Non small cell carcinoma of the lung medical therapy#Negative EGRF and ALK or unknown mutation|Click here for the treatment of negative sensitizing EGFR and ALK mutation metastatic disease]]}} | |||
{{familytree/end}} | {{familytree/end}} | ||
<br> | <br> |
Revision as of 14:46, 24 June 2014
Non Small Cell Lung Cancer Microchapters |
Differentiating Non Small Cell Lung Cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Non small cell lung cancer medical therapy metastatic cancer On the Web |
American Roentgen Ray Society Images of Non small cell lung cancer medical therapy metastatic cancer |
FDA on Non small cell lung cancer medical therapy metastatic cancer |
CDC on Non small cell lung cancer medical therapy metastatic cancer |
Non small cell lung cancer medical therapy metastatic cancer in the news |
Blogs on Non small cell lung cancer medical therapy metastatic cancer |
Directions to Hospitals Treating Non small cell carcinoma of the lung |
Risk calculators and risk factors for Non small cell lung cancer medical therapy metastatic cancer |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alonso Alvarado, M.D. [2]
Overview
Medical Therapy for Metastatic Non-Small Cell Lung Cancer
What the specific subtype according to the specific histological characteristics of the tumor? | |||||||||||||||||||||||||||||||||||||||||||||
| Squamous cell carcinoma | ||||||||||||||||||||||||||||||||||||||||||||
Is the patient a smoker or former smoker? | |||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||
Perform specific EGFR and ALK mutation testing: What is the specific mutation? | Perform specific EGFR and ALK mutation testing: Is there a mutation in any of those genes present? | ||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||
Sensitizing EGFR mutation | ALK mutation | Negative EGFR and ALK | Click here for the squamous cell carcinoma specific treatment | ||||||||||||||||||||||||||||||||||||||||||
Click here for the sensitizing EGFR mutation specific treatment | Click here for the specific therapy for the ALK mutation specific treatment | Click here for the treatment of negative sensitizing EGFR and ALK mutation metastatic disease | |||||||||||||||||||||||||||||||||||||||||||
Metastatic adenocarcinoma, large cell carcinoma and not specified non-small cell carcinoma
The algorithms for the treatment of metastatic non small cell carcinoma of the lung are based on the 2014 NCCN Non-Small Cell Lung Cancer guidelines.[1]
Positive sensitizing EGFR mutation
Was the mutation discovered before the initiation of first line therapy? | |||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||
Initiate erlotinib or afatinib | Suspend or complete chemotherapy and initiate erlotinib or afatinib OR Add erlotinib or afatinib to chemotherapy regimen | ||||||||||||||||||||||||||||||||||||||||||||||||||
Did the tumor progress or respond? | |||||||||||||||||||||||||||||||||||||||||||||||||||
Tumor progression | Positive response or stable tumor | ||||||||||||||||||||||||||||||||||||||||||||||||||
Symptomatic disease | Asymptomatic disease | ||||||||||||||||||||||||||||||||||||||||||||||||||
Systemic metastasis | Brain metastasis | Continue treatment | |||||||||||||||||||||||||||||||||||||||||||||||||
Multiple metastasis | Single metastasis | Multiple metastasis | Single metastasis | ||||||||||||||||||||||||||||||||||||||||||||||||
Continue treatment, consider local therapy | Continue treatment, consider whole brain radiation therapy | Continue treatment, consider local therapy | Consider platinum doublet with or without Bevacizumab AND/OR Erlotin | ||||||||||||||||||||||||||||||||||||||||||||||||
If findings suggestive of progression of the disease are present, click here for the third line therapy | |||||||||||||||||||||||||||||||||||||||||||||||||||
Positive ALK mutation
Was the mutation discovered before the initiation of first line therapy? | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Initiate crizotinib | Suspend or complete chemotherapy and initiate crizotinib | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Did the tumor progress or respond? | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tumor progression | Positive response or stable tumor | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Symptomatic disease | Asymptomatic disease | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Systemic metastasis | Brain metastasis | Continue treatment or change to certinib according to the degree of disease | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Multiple metastasis | Single metastasis | Multiple metastasis | Single metastasis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Continue treatment, consider local therapy | Continue treatment, consider whole brain radiation therapy | Continue treatment, consider local therapy | Initiate certinib OR Consider platinum doublet with or without Bevacizumab AND/OR Erlotinib | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
If findings suggestive of progression of the disease are present, click here for the third line therapy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Negative EGRF and ALK or unknown mutation
What is the performance status (PS) of the patient? | |||||||||||||||||||||||||||||||||||||||||||||||
0-1 | 2 | 3-4 | |||||||||||||||||||||||||||||||||||||||||||||
Doublet chemotherapy OR Bevacizumab + Chemotherapy OR Cetuximab/vinorelbine/cisplatin | Chemotherapy | Supportive care | |||||||||||||||||||||||||||||||||||||||||||||
What was the tumor response to the treatment? | |||||||||||||||||||||||||||||||||||||||||||||||
Progression | Positive response or stable tumor | ||||||||||||||||||||||||||||||||||||||||||||||
Administer 4-6 cycles and assess progression of the disease | |||||||||||||||||||||||||||||||||||||||||||||||
PS 0-2 | PS 3-4 | Tumor progression | Positive response or stable tumor | ||||||||||||||||||||||||||||||||||||||||||||
Initiate docetaxel or pemetrexed or erlotinib or gemcitabine | Provide supportive care | Initiate docetaxel or pemetrexed or erlotinib or gemcitabine | Continuation maintenance (cetuximab or gemcitabine) OR Switch maintenance (erlotinib or decetaxel) OR Close observation | ||||||||||||||||||||||||||||||||||||||||||||
Initiate docetaxel or pemetrexed or erlotinib or gemcitabine | |||||||||||||||||||||||||||||||||||||||||||||||
If findings suggestive of progression of the disease are present, click here for the third line therapy | |||||||||||||||||||||||||||||||||||||||||||||||
Metastatic squamous cell carcinoma
What is the performance status (PS) of the patient? | |||||||||||||||||||||||||||||||||||||||||||||||
0-1 | 2 | 3-4 | |||||||||||||||||||||||||||||||||||||||||||||
Doublet chemotherapy OR Cetuximab/vinorelbine/cisplatin | Chemotherapy | Suportive care | |||||||||||||||||||||||||||||||||||||||||||||
What was the tumor response to the treatment? | |||||||||||||||||||||||||||||||||||||||||||||||
Progression | Positive response or stable tumor | ||||||||||||||||||||||||||||||||||||||||||||||
Administer 4-6 cycles and assess progression of the disease | |||||||||||||||||||||||||||||||||||||||||||||||
PS 0-2 | PS 3-4 | Tumor progression | Positive response or stable tumor | ||||||||||||||||||||||||||||||||||||||||||||
Initiate docetaxel or erlotinib or gemcitabine | Provide suportive care | Initiate docetaxel or erlotinib or gemcitabine | Continuation mantainance (cetuximab or gemcitabine) OR Switch mantainance (erlotinib or decetaxel) OR Close observation | ||||||||||||||||||||||||||||||||||||||||||||
Initiate docetaxel or pemetrexed or erlotinib or gemcitabine | |||||||||||||||||||||||||||||||||||||||||||||||
If findings suggestive of progression of the disease are present, click here for the third line therapy | |||||||||||||||||||||||||||||||||||||||||||||||
Multiple lung cancers
Is there suspicion of multiple lung cancers? | |||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||
Administer treatment according to the TNM stage of the tumor | |||||||||||||||||||||||||||||||||
Is the disease is confined to the chest or is there systemic proliferation? | |||||||||||||||||||||||||||||||||
Disease confined to the chest | Systemic proliferation | ||||||||||||||||||||||||||||||||
Assess the mediastinal lymph nodes in order to determine the N stage of the tumor | Click here for the treatment of systemic metastasis | ||||||||||||||||||||||||||||||||
What is the N stage of the tumor? | |||||||||||||||||||||||||||||||||
N0-1 | N2-3 | ||||||||||||||||||||||||||||||||
Is the patient symptomatic? | Click here for the treatment of systemic metastasis | ||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||
Is the lesion a solitary nodule or are there multiple nodules? | |||||||||||||||||||||||||||||||||
Solitary nodule | Multiple nodules | ||||||||||||||||||||||||||||||||
What is the risk of turning into a symptomatic disease? | |||||||||||||||||||||||||||||||||
High | Low | ||||||||||||||||||||||||||||||||
Is definitive local therapy possible? | Observation | ||||||||||||||||||||||||||||||||
No | Yes | ||||||||||||||||||||||||||||||||
Consider palliative chemotherapy with or without local radiation therapy | Administer one of the following tratments:
| ||||||||||||||||||||||||||||||||
Click here for the treatment of systemic metastasis | Click here for the follow-up recommendations and treatment of recurrence and metastasis | ||||||||||||||||||||||||||||||||